SCA
EPZM

SAC Capital Advisors’s Epizyme, Inc EPZM Stock Holding History

SAC Capital Advisors’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-275,030
Closed -$6.26M – 1163
2014
Q1 		$6.26M Buy
275,030
+253,830
+1,197% +$7.69M 0.03% 521
2013
Q4 		$441K Buy
21,200
+18,657
+734% +$541K ﹤0.01% 1223
2013
Q3 		$102K Buy
+2,543
New +$86.1K ﹤0.01% 1690

Other funds holding EPZM

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

SAC Capital Advisors's EPZM Position: Q2 2014 in Review

SAC Capital Advisors sold out of Epizyme, Inc (EPZM) in Q2 2014, closing a stake of 275,030 shares — an estimated $6.26M sold.

SAC Capital Advisors first reported a position in EPZM in Q3 2013 and held it in 3 quarters. The position peaked at $6.26M in Q1 2014. 83 funds tracked by Wall St. Rank hold EPZM as of Q2 2014.

  • SAC Capital Advisors reported no remaining Epizyme, Inc position as of Q2 2014 after selling out during the quarter.
  • SAC Capital Advisors sold 275,030 Epizyme, Inc shares in Q2 2014, an estimated $6.26M.
  • SAC Capital Advisors first reported a position in Epizyme, Inc in Q3 2013 and held it in 3 quarters.
  • SAC Capital Advisors's Epizyme, Inc position peaked at $6.26M in Q1 2014.
  • 83 funds tracked by Wall St. Rank held Epizyme, Inc as of Q2 2014.

Based on SAC Capital Advisors's 13F filing for Q2 2014.